Market Overview

UPDATE: Bank of America Downgrades Hospira to Neutral on Cash Flow Guidance

Related HSP
Hospira Granted Temporary Restraining Order Against FDA, Shares Pop Higher
BioScrip Posts Wider-than-Expected Q2 Loss on Poor Margins

Bank of America downgraded Hospira (NYSE: HSP) from Buy to Neutral and reduced the price target from $44.00 to $38.00.

Bank of America commented, "HSP announced ‘13 guidance on its 4Q earnings call, and while management's revenue and EPS outlook is roughly consistent with ours, we were disappointed by cash flow guidance. In addition, HSP announced that (1) it is in the midst of deciding on its strategy for remediating its pumps business, which creates some new uncertainty (could have implications for costs and potentially for revenue), and (2) the long-awaited FDA re-inspection of the Rocky Mount facility has just begun, and management plans to summarize the results when complete (guidance assumes a “successful” outcome), potentially within a month or two."

Hospira closed at $34.03 on Tuesday.

Posted-In: Bank of AmericaAnalyst Color Downgrades Analyst Ratings

 

Related Articles (HSP)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters